Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
Become a Member | Sign in
Home>News>This Article

American CryoStem Announces "ACS Laboratory Services"

Published: Friday, January 13, 2012
Last Updated: Friday, January 13, 2012
Bookmark and Share
This new branding reflects the company's increasing commercialization of products and services developed for its proprietary clinical tissue processing methodologies.

CryoStem have begun offering the first of these products for sale and license which are based on their granted patent (Cell Culture Media, Kits and Methods of Use," (US 7,898,205 B2)). The product line is the first patented culture, growth and differentiation media specifically designed for use with adipose derived stem cells (ADSC) and is ideally suited for the conversion of new ADSC therapies from research to clinical application. The media is available in both research and clinical grade, in 100ml to 1 liter ready to use quantities. The product line includes undifferentiated growth media, and adipogenic, chondrogenic, and osteogenic differentiation media. The clinical grade media are free from animal (xenomorphic) serum and additives which make them ideally suited for the expansion and differentiation of ADSCs intended for clinical use.

The company made their first commercial sale of our media products this month and have begun marketing to increase industry recognition and sales. They currently have a new website under construction to support this new product offering and all future products and services commercialized by ACS Laboratories.

David Moscatello, Chief Scientist, stated, "I am very excited to have begun offering these products to my colleagues working with ADSCs and believe that these products will assist them in the acceleration of their treatment development. We have additional products and services in various stages of development based on our patented technologies and core adipose tissue processing platform that will be unveiled during the coming year."

John S. Arnone, CEO, stated, "We are very enthusiastic to be able to announce the commercialization and initial sales revenue from products developed from our recently issued patent. During 2011 we have been the beneficiary of increased dialogue and involvement from both doctors and researchers regarding our services and products under development. Our overall philosophy concerning the services offered by ACS Laboratories is to offer clinical grade products that are free from animal materials that can relieve some of the costs and the significant and increasing regulatory burdens for developers of cellular technologies. These burdens are evidenced in the U.S. Department of Health and Human Services and the FDA's regulations and guidance for manufacturers and developers in relation to the inclusion of xenomorphic (animal) material in the manufacturing and marketing of new and existing cellular products."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Study Implicates Glial Cells in Fragile X Syndrome
The genetic defect behind a common cause of mental retardation affects not only neurons but also the more numerous glial cells in the brain.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
A Step Forward in Building Functional Human Tissues
Researchers at Wyss Institute have bioprinted a tubular 3D renal architecture that recapitulates functions of the kidney.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos